Clinical Trial: A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07722767) titled 'A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients' on July 15.

Brief Summary: A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.

Study Start Date: Oct. 15, 2026

Study Type: INTERVENTIONAL

Condition: AML (Acute Myeloid Leukemia)

Intervention: DRUG: CLN-049

CLN-049 will be initiated using two step-up doses (SUDs), followed by the fir...